The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...

Biotechnology and biomedical engineering are distinct yet impactful fields shaping healthcare's future. Biotechnology delves ...

Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

North Carolina’s economy continues to outpace that of most competitors. The latest employment report from the U.S. Bureau of ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...

Abviax's Obefazimod shows strong potential in ulcerative colitis treatment. Upcoming phase 3 trial data in Q3 2025 is a key ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...